Lv1
38 积分 2024-05-22 加入
BIO89-100, a GlycoPEGylated FGF21 Analog, Improved Serum Lipids and Extended Half-Life in a Controlled Single Ascending Dose Trial in Healthy Subjects†
2天前
已完结
The development of oral semaglutide, an oral GLP-1 analog, for the treatment of type 2 diabetes
6天前
已完结
Minimal Physiologically Based Pharmacokinetic-Pharmacodynamic (mPBPK-PD) Model of N-Acetylgalactosamine–Conjugated Small Interfering RNA Disposition and Gene Silencing in Preclinical Species and Humans
10天前
已完结
Toward Small-Molecule Inhibition of Protein–Protein Interactions: General Aspects and Recent Progress in Targeting Costimulatory and Coinhibitory (Immune Checkpoint) Interactions
10天前
已完结
Application of Model‐Informed Drug Development in Dose Selection and Optimization for siRNA Therapies
11天前
已完结
FGF21 Analogues and MASLD: A Summary of Preclinical and Clinical Data
13天前
已完结
Network Meta‐Analysis: Comparison of Pharmacological Therapies in Compensated Metabolic Dysfunction‐Associated Steatohepatitis Cirrhosis for Fibrosis Regression and MASH Resolution
13天前
已完结
Safety and efficacy of GLP-1/FGF21 dual agonist HEC88473 in MASLD and T2DM: A randomized, double-blind, placebo-controlled study
15天前
已完结
Efimosfermin alfa (BOS-580) once per month in people with metabolic dysfunction-associated steatohepatitis with F2 or F3 fibrosis: results from a 24-week, randomised, double-blind, placebo-controlled, phase 2 trial
15天前
已完结
Efimosfermin alfa (BOS-580), a long-acting FGF21 analogue, in participants with phenotypic metabolic dysfunction-associated steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial
15天前
已完结
皖公网安备34019202002308
